Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISION Study of local iloprost for bone healing in high-risk fractures
2026-527568-34-00Phase 2Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of iloprost in bone fracture (Fx) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Radiological fracture healing at Week 18 assessed by CT. Planned start Oct 2026; status: authorised.
02
Drugs
iloprost
03
Conditions
bone fracture (Fx)
Beyond the preview
Go deeper on 2026-527568-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527568-34-00.